Eliana Biundo is the mRNA Development Vaccine Value Evidence Lead at GSK. In her role she is responsible for the global value evidence strategy of mRNA vaccines.
She previously worked as a Senior Manager in the Deloitte Health Economics and Outcomes Research team.
With over 9 years’ experience in health economics and health policy research, she is particularly passionate about immunisation policy and vaccines market access.

Eliana’s mother tongue is Italian. She also has fluency in English and French and beginner’s command in Spanish and Dutch.